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Plasmacytoid dendritic cells (pDC) are a rare subset of leukocytes equipped with Fcγ and
Fcε receptors, which exert contrary effects on sensing of microbial nucleic acids by endo-
somal Toll-like receptors. In this article, we explain how pDC contribute to the immune
response to Staphylococcus aureus. Under normal circumstances the pDC participates in
the memory response to the pathogen: pDC activation is initiated by uptake of staphy-
lococcal immune complexes with IgG or IgE. However, protein A-expressing S. aureus
strains additionally trigger pDC activation in the absence of immunoglobulin. In this con-
text, staphylococci exploit the pDC to induce antigen-independent differentiation of IL-10
producing plasmablasts, an elegant means to propagate immune evasion. We further dis-
cuss the role of type I interferons in infection with S. aureus and the implications of these
findings for the development of immune based therapies and vaccination.
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INTRODUCTION
Plasmacytoid dendritic cells (pDC) constitute a rare, but ubiq-
uitously present leukocyte subset. They were originally described
as professional interferon-producing cells (IPC) (1, 2), because of
their capacity to secrete high concentrations of type I interferons
(IFN-I) (mainly IFN-α) that can reach systemic activity [reviewed
in Ref. (3, 4)].
Numerous studies elucidate pDC function in different types of
infection, autoimmune disease entities and in maintenance of tol-
erance [reviewed in Ref. (5)]. Most importantly, they have made
us aware of the fact that there are pDC functions beyond IFN
secretion. Despite their versatility only few studies described pDC
activation and addressed its role in the host response to Staphy-
lococcus aureus (6–12). Thus, their function in the daily combat
with colonizing and infecting S. aureus strains remains to be inves-
tigated. In this article, we summarize the available findings and
discuss the potential implications for immune based therapies and
vaccine design.
WELL-EQUIPPED VIRAL SENSORS
Type I interferons are essential for antiviral immune defense. Early
studies postulated that pDC represent specialized viral sensors in
first line innate immune defense against viruses [reviewed in Ref.
(13)]. Identification of Toll-like receptors (TLR)-7 and -9 as the
major triggers for pDC activation fostered this concept because
RNA viruses such as influenza, RSV, VSV and HIV engage TLR7,
and DNA viruses, i.e., HSV and EBV, activate pDC in a TLR9-
dependent manner. Nevertheless, under defined circumstances
cytosolic, RIG-I like-receptor-dependent recognition also occurs
(8, 14–16).
Subsequent studies elucidated pDC-mediated effects on
the adaptive immune response. The major findings implied
that pDC-derived IFN-α supports Th1 responses [reviewed in
Ref. (17)] and enhances the formation of antibody secreting cells
in response to virus (18).
The relevance of pDC and IFN-I in antiviral immune defense is
strongly supported by the multitude of viral immune escape mech-
anisms interfering with the induction of IFN-I or its direct effect
on intracellular viral replication. Depletion of pDC in in vivo infec-
tion models revealed that pDC contribute to virus clearance and
constrain inflammation during infection (19–21). Concomitant
expression of HIV permissive receptors, i.e., CD4, CXCR4, CCR5
[reviewed in Ref. (22, 23)], and viral restriction factors (Figure 1A,
left panel), i.e., APOBEG3G (24), CD317/tetherin/BST2 (25), ILT7
(26), and SamHD1 turns pDC into “viral traps,” e.g., important
target cells for viral infection albeit well-equipped and highly
specialized on intracellular antiviral defense (Figure 1A, left
panel).
PERPETUATORS OF AUTOIMMUNE DISEASE AND ALLERGY
Due to their highly efficient IFN-α producing capacity it was
obvious that pDC might be involved in autoimmune disease. In
this disease context, pDC were shown to be activated by immune
complexes (IC) consisting of autoantibodies binding endogenous
chromatin or RNA and activating TLR9 or TLR7, respectively
[reviewed in Ref. (27–30)]. Uptake of IC was mediated via FcγRIIA
(CD32A), a positive regulatory receptor for IgG (Figure 1A, mid-
dle panel). IC-induced pDC-derived IFN-α is thought to account
for elevated IFN-I levels in patients with systemic lupus erythe-
matosus, Behcet’s disease, and Sjögren’s syndrome (31–33). The
ubiquitous presence of pDC facilitates systemic effects of IFN-
α. This cytokine contributes to the development and severity
of disease by enhancing autoantibody production and driving
inflammation [reviewed in Ref. (34)].
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FIGURE 1 | Plasmacytoid dendritic cells function in different immune
contexts. (A) pDC fulfill different effector functions. I. Sensors for
intracellular pathogens. pDC are target cells for viral infection because they
express cell surface receptors utilized for virus entry, i.e., HIV permissive
receptors CD4, CXCR4, and CCR5. Endosomal TLR7 and TLR9 mediate
recognition of RNA and DNA viruses, respectively. IFN-I synthesis and viral
restriction factors counteract viral infection and intracellular replication.
Surface receptors such as ILT7 and BDCA2 regulate pDC function. II.
Immune complex-mediated activation. pDC express FcγRIIA and FcεRI.
These receptors are engaged by immune complexes consisting of IgG and
bacteria, viruses or endogenous nucleic acids or IgE-bound allergens.
Binding of FcγRIIA promotes access of IgG-complexed nucleic acids to
endosomal TLR and enables pDC-derived IFN-α release. FcεRI ligation
inhibits TLR9-induced IFN-α secretion and induces IL-10 production and Th2
polarization. III. Tolerance induction. pDC promote tolerance via induction of
Treg. Tolerogenic function has been associated with high PDL-1 and low
CD86 expression, release of IL-10, expression of CCR9, IDO, ICOS-L, and
low CD2. Expression of CD36 and CD61 among other surface receptors
enables apoptotic cell recognition. (B) S. aureus-induced pDC activation
occurs in an FcγRIIA-dependent (I) and -independent (II) fashion. I (left): pDC
are activated by bacterial immune complexes (IC) with anti-staphylococcal
IgG. This activation requires prior generation of IgG and therefore forms part
of a secondary immune response. IC-mediated engagement of the FcγRIIA
promotes access of staphylococcal nucleic acids to endosomal TLR7/9,
which induces secretion of IFN-α. II (right): S. aureus strains expressing high
levels of protein A (SpA) stimulate pDC in the absence of IgG and IC
formation. This virulence factor-dependent mechanism for pDC activation
triggers release of IFN-α via activation of endosomal TLR7/9. Activated pDC
support SpA-dependent B cell expansion and differentiation into IL-10
secreting plasmablasts. B cell-derived IL-10 production, a hallmark of
regulatory B cell function, prevents T cell responses by inhibiting antigen
presentation by dendritic cells and macrophages.
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Similarly to autoantigens allergens complexed with IgE can acti-
vate pDC. However, ligation of the FcεRI expressed on pDC has
quite distinct effects from those induced via FcγRIIA activation:
FcεRI aggregation has negative regulatory impact on influenza
virus and TLR9-mediated release of IFN-I from pDC (35–37).
On the contrary, aggregation of the FcεRI promotes IL-10 secre-
tion and shifts the T cell response toward an allergy related-Th2
response (35), an effect supported by the absence of IFN-I. A cor-
relation of serum IgE with an increased pDC/mDC ratio and a
Th2 response underlines the clinical relevance of these findings
(35, 36, 38).
Taken together, these examples demonstrate that pDC function
varies depending on the disease entity. They highlight the dom-
inant role of IC recognition in pDC activation and the opposite
effects of differentially composed IC on pDC function.
MEDIATORS OF TOLERANCE
More recently, several groups have drawn our attention to the
tolerogenic properties of pDC [reviewed in Ref. (5, 39)]. This
includes immune regulatory function in graft-versus-host disease
(40–42), cancer (26, 43), infection (44–46), autoimmune disease
(47–49), and tolerance to oral antigens (50). Furthermore, pDC
recognize membrane microparticles released from apoptotic cells
(16, 51) and play a crucial role in the promotion of tolerance upon
apoptotic cell recognition (52).
To date the tolerogenic function has been attributed to the
induction of T regulatory cells (44, 53–59). Release of pDC-
derived IL-10 and expression of IDO, PD-L1, and ICOS-L rep-
resent the mainstay for Treg induction (51, 54, 55, 57, 60–67)
(Figure 1A, right panel). Furthermore, pDC effector function is
subject to strong regulation by the cellular environment (43, 44,
60, 68–70): while TGFβ exposure promotes pDC-derived secre-
tion of high levels of IL-6 and development of Th17 cells (71),
soluble factors released from macrophages exposed to apop-
totic cells prime pDC for Treg induction (52). Furthermore,
TNF, ROS, IL-10, PGE2, and TGFβ in Peyer’s patches, tumor
cells, or adjacent monocytes modulate cytokine secretion pat-
terns and decrease IFN-α secretion levels in pDC (68, 72–75),
concomitantly reducing their Th1 induction potential [reviewed
in Ref. (76)].
In this context, it is further important to note that IFN-I do not
exclusively act as amplifiers of inflammatory processes but also
participate in Treg induction and suppression of T cells, B cells,
and innate immune cells (17, 77–89). Depending on the cellular
context pDC-derived IFN-I may, thus, play a role in terminating
or perpetuating the adaptive immune response.
RECOGNITION OF STAPHYLOCOCCUS AUREUS
SENSING OF STAPHYLOCOCCUS AUREUS
For a long time, pDC were considered specialized mediators of
antiviral defense and only few reports addressed their ability to
respond to fungi and bacteria [reviewed in Ref. (90)]. These stud-
ies focused on intracellular bacteria (91–96). Induction of IFN-I
by extracellular bacteria, was only observed with Escherichia coli
and, most importantly, S. aureus (9–11, 97, 98). The cellular source
and the molecular mechanism triggering IFN-I release remained
ill-defined.
This prompted us to investigate how S. aureus induces IFN-
I secretion. Our data identified pDC as the major source for S.
aureus-induced release of IFN-α from human peripheral blood
leukocytes (7, 8). This finding confirmed earlier reports on IFN-α
secretion in response to stimulation with S. aureus in a murine DC
cell line (9) and initial descriptions of S. aureus-responsive IPCs
(10, 11). Michea et al. further demonstrated uptake of S. aureus
into pDC and secretion of IFN-α, TNF, and IL-6 (6). We further
detected pDC-derived IL-1β secretion and low levels of IL-10 in
response to S. aureus (7).
As with viruses any inhibition of endosomal maturation and
of TLR7 and TLR9 activation interfered with S. aureus-mediated
IFN-α secretion (7, 8) and staphylococcal DNA and RNA induced
pDC-derived IFN-α production (8). Furthermore, stimulation
with viable staphylococci was superior to that induced by non-
replicating (heat- or UV-killed) cells, a finding attributed to a
higher content in microbial nucleic acids and the presence of vita-
PAMPs (99). Thus, pDC-derived IFN-α secretion triggered by S.
aureus is driven by intracellular nucleic acid recognition.
Moreover, soluble factors released from tonsillar epithelial cells
exposed to S. aureus inhibit pDC-derived cytokine production (6)
and release of IFN-α in response to S. aureus was reduced in pDC
isolated from patients suffering of hepatitis B virus infection (100).
Taken together, these data highlight the importance of the cellu-
lar environment in the regulation of pDC function in S. aureus
infection.
pDC ACTIVATION FORMS PART OF THE MEMORY RESPONSE TO
S. AUREUS
Interestingly, the available reports indicated that only S. aureus
triggers IFN-α, while other extracellular bacteria including coag-
ulase negative staphylococci or Streptococcus pyogenes lack the
ability to activate pDC (8, 90, 101). Figure 2A elucidates a key
finding: rapid uptake of S. aureus into pDC is mediated by human
serum containing IgG, but is absent if pDC are stimulated in serum
lacking Ig with binding affinity to human FcγRs (chicken serum).
Furthermore, neutralization of the FcγRIIA on pDC or absence of
serum IgG blocks bacterial endocytosis and, thus, prevents access
of bacterial nucleic acid to endosomal TLRs and subsequent IFN-α
induction (8).
Altogether, it became clear that S. aureus-induced release of
pDC-derived IFN-α depends on the formation of bacterial IC as
propagated in autoimmune disease (8) (Figure 1B, left panel).
These complexes contain anti-bacterial IgG that engages the
FcγRIIA and promotes uptake of bacteria. Consequently, pDC
activation occurs in an antigen-specific manner, e.g., S. aureus-
specific IgG was required for the induction of IFN-α release. This
was demonstrated by the absence of IFN-α induction when IC
formation was prevented by use of a S. aureus strain deficient in
the antigen targeted by the antibody (8).
The existence of strain- or species-specific serum IgG antibody
is, thus, a key determinant in IC-induced pDC activation (8). Due
to continuous exposure of humans (and animals) to S. aureus sera
normally contain IgG specific for S. aureus, which explains their
predisposition to respond to S. aureus with IFN-α production.
This observation further explains why other extracellular bacteria
lack IFN induction potential: they are less likely to mount an IgG
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FIGURE 2 | Plasmacytoid dendritic cell activation by S. aureus requires
the uptake of bacterial immune complexes. (A) Cellular uptake of S. aureus
depends on the presence of mammalian IgG. pDC were purified with
anti-BDCA-4 microbeads and stimulated for 2 h at 37°C with heat-inactivated
(1 h 65°C) GFP-expressing S. aureus strain SA113 WT (green) in medium
supplemented with 5% chicken serum (upper panel) or 5% human serum
(lower panel) at 37°C. DAPI (blue) was used as nuclear counterstain. Cells
were visualized by confocal microscopy. (B,C) IgG subclass requirements for
bacterial immune complex formation. (B)Western blot analysis of IgG
subclass distribution in two patients with selective IgG deficiency. Bacterial
protein lysates from USA300 (1), Newman (2), Wood46 (3), and SA113 ∆spa
(4) were loaded on SDS-PAGE. Western blot analysis visualizes the IgG
subclasses present in serum from patient 1 (IgG3 only) and patient 2 (IgG1 and
IgG3 only, selective IgG2/4-deficiency). Membranes were incubated with
serum followed by biotinylated anti-human IgG subclass antibodies and
streptavidin-HRP as described in Ref. (7). (C) pDC medium was supplemented
with 5% chicken serum (CH), autologous serum [healthy adult donor (A)], or
serum from patient 1 (B) or patient 2 (C). IFN-α release from pDC was
quantified in the supernatants after 24 h stimulation. The graph summarizes
the results obtained in five experiments with independent pDC donors.
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memory response because humans are either rarely exposed to the
bacterial species (for example S. carnosus found in meat) or they
do not trespass the skin and/or mucosal barriers and, thus, remain
secluded from the blood and lymphoid compartments and the
necessity to mount an IgG response (for example S. epidermidis,
resident of the skin). As a consequence, only individual donors
display a pDC response to coagulase negative staphylococci while
donor pDC normally respond to S. aureus.
To further elucidate the IC composition we retrieved to sera
from children with selective IgG deficiencies. The data obtained
showed that the presence of anti-S. aureus IgG1 and/or IgG3
(Figure 2B) is sufficient for the induction of pDC-derived IFN-
α (Figure 2C). Thus, the presence of IgG2 and IgG4 does not
represent a prerequisite for pDC activation.
Taken together, the available findings imply that prior genera-
tion of S. aureus-specific IgG1/3 is a mainstay for pDC activation.
We, therefore, previously proposed that pDC activation is part of
the secondary immune response to the microbe (Figure 1B, left
panel). Notably, FcγRII-dependent induction of IFN-I or activa-
tion of pDC was also reported for viruses that do not actively
infect pDC (102–107). We, therefore, concluded that IC-mediated
pDC activation represents the physiological immune response to
infection.
EXPLOITING pDC FOR IMMUNE EVASION
It is well acknowledged that S. aureus induces T cell-independent
polyclonal B cell activation by targeting of VH3+ B cell receptors
with the immunoglobulin-binding protein“protein A”(108). Sim-
ilarly to B cells, staphylococcal protein A also induces pDC-derived
IFN-α, thus circumventing the requirement for S. aureus-specific
IgG and IC formation (7). These findings incremented earlier
reports that proposed a role for protein A in IPC activation (10,
12). This alternative, albeit weaker, mechanism for pDC acti-
vation is, again, mediated by bacterial nucleic acid recognition
because interference with endosomal TLR signaling abrogated
pDC-derived IFN-α secretion (7). However, the exact cellular
mechanisms mediating protein A-dependent uptake of nucleic
acids into pDC remain to be clarified. Based on the results shown
in Figure 2A, it can be speculated that IC/FcγRIIA-mediated pDC
activation promotes rapid uptake of whole bacteria while protein
A-induced activation could be slower, less efficient, and might be
mediated by protein A-bearing peptidoglycan particles complexed
with nucleic acids.
Nevertheless, this form of pDC activation is noteworthy,
because it depends on a bacterial virulence factor. It, therefore,
resembles viral pDC infection and might contribute to disease
pathology rather than immune defense (Figure 1B, right panel).
Interestingly, protein A-dependent cytokine induction mainly
affected pDC-derived IFN-α and, additionally, monocyte-derived
IL-10 (7). Well in line with a report on the immune recognition
of S. aureus in monocytes (109) we did not detect IFN-α secretion
in monocytes. IL-1β levels in monocytes were lower than those in
pDC and did not correlate with protein A expression levels (7), a
finding well compatible with its induction by a completely distinct
set of bacterial and host factors, i.e., hemolysins, peptidogly-
can degradation, ATP, ASC, cryopyrin, and Nlrp3 inflammasome
activation (110–114).
What is more, activation of B cells was not only paralleled
by S. aureus-induced activation of pDC but presence of pDC
was a requirement for B cell proliferation and differentiation
in response to stimulation with S. aureus (7). Although, syn-
ergy of B cells and pDC has been described in other contexts
(115–119), it is often viewed as an effect of IFN-I on B cells.
However, IFN-α inhibited S. aureus-induced B cell proliferation
as in Ref. (120–122) and pDC function cannot be substituted by
IFN-α or pDC supernatants indicating that cell-to-cell contact is
required (7, 119).
Altogether, this study highlighted the fundamental role of pDC
in promoting polyclonal B cell expansion and mediating B cell-
derived IL-10 production in an IFN-I independent manner (7).
Based on these results, we propose that S. aureus exploits pDC to
trigger polyclonal expansion of “regulatory B cells” and suppres-
sion of anti-bacterial T cell responses by B cell-derived IL-10 (123)
(Figure 1B, right panel).
ROLE OF TYPE I INTERFERON IN S. AUREUS INFECTION
In contrast to virus infection, the role of IFN-α/β production in
innate defense against bacterial pathogens is less clear and often
paradox. While IFNαR signaling in some cases is required for bac-
terial clearance (124, 125), it supports hyperinflammation and
increases disease severity in others (126). Albeit earlier studies
reported release of IFN-α from human PBL in response to S. aureus
(9–12, 127) a more recent study demonstrated that lysozyme resis-
tance of S. aureus prevents IFN-β induction (109). Degradation-
sensitive mutants induced higher levels of IFN-β, which mediated
bacterial clearance in vitro and in vivo at the cost of increased
inflammation and necrosis in vivo. IFN-β induction in monocytes
was MyD88-dependent but independent of TLR, thus, arguing for
a role of IL-1β or IL-18 and the inflammasome in this process.
Alternatively, in the murine model TLR13-mediated sensing of
staphylococcal RNA might play a contributory role in S. aureus
recognition (128).
In other S. aureus infection models lack of IFNαR or TLR9
protects mice against S. aureus pneumonia (129, 130), an observa-
tion attributed to reduced inflammation. On the contrary, IFN-I
release in LCMV infection decreases IL-12 and IFNγ production
in response to S. aureus and predisposes mice for superinfection
with S. aureus by inducing neutropenia (131, 132). Nevertheless,
CpG ODN-mediated induction of IFN-α in pDC was protective
against S. aureus pneumonia in a hemorrhagic shock model (133)
and IFNα mediated resistance of host cells against S. aureus alpha
toxin (134). In views of these conflicting results, we conclude that
the role of type I interferon in the immune response to S. aureus
is still ill-defined.
IMPLICATIONS AND OUTLOOK
Our summary of pDC function in the immune response illus-
trated that pDC function depends on the cellular environment
and the disease entity (Figure 1A). pDC and IFN-I have partially
overlapping functions and exert numerous, partially antagonistic
regulatory functions within the immune response. The complexity
of this cooperation is hard to tackle.
In the context of S. aureus infection,we have proposed that pDC
serve two purposes (Figure 1B): firstly (Figure 1B, left panel), pDC
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respond to uptake of IgG-containing bacterial IC with produc-
tion of IFN-α. Thus, pDC activation forms part of the secondary
immune response to the pathogen. Here, pDC might enhance the
efficacy of memory T and B cell responses and possibly limit the
priming of naïve lymphocytes. Furthermore, preferential forma-
tion of anti-staphylococcal IgG4, an IgG subclass with low affinity
to the human FcγRIIA (7, 135–137), could contribute to avoidance
of pDC activation by IgG1 and IgG3-bearing IC (Figures 2B,C),
thereby weakening the memory response.
Notably, to date no study has addressed the role of IC consisting
of bacteria and IgE in pDC activation. Since it is well-known that
there is significant production of IgE against S. aureus and its tox-
ins in nasal polyposis, asthma, and atopic dermatitis pDC might
serve as important promoters of Th2-based immune responses
and staphylococcal colonization in these diseases (138–143).
Secondly, S. aureus induces a virulence factor-driven activation
of pDC (Figure 1B, right panel). Our data suggest that pathogen-
driven activation of pDC enhances polyclonal B cell expansion
and the development of suppressory B cells that secrete IL-10.
Indeed, depletion of B cells from PBMC increases IFNγ pro-
duction in response to S. aureus (Bekeredjian-Ding, unpublished
observation). Activation of pDC by S. aureus might addition-
ally promote the formation of Tregs (144), which develop in an
IFN-I-dependent and -independent manner (17, 39, 145). Never-
theless, pDC-derived IFN-α is likely to enhance proinflammatory
effects exerted by aberrant IC formed by Ig binding to protein A
and deposited in the tissues (146), superantigen-mediated T cell
activation (147), or invasion of epithelial cells (129). It is further
unknown whether and how pDC contribute to S. aureus protein
A-mediated expansion of B cells and autoantibody production in
Wegener’s granulomatosis (148).
Taken together, the available studies illustrate that pDC (and
IFN-I) fulfill partially unknown and conflicting roles in anti-
bacterial defense and maintenance of tolerance. It is further
unclear whether the active role of pDC in the memory response to
S. aureus is to limit or to propagate the ongoing adaptive immune
response. In views of the inflammatory potential of IFN-I future
studies will need to evaluate whether therapeutical interference
with pDC activation or IFN-I limits disease severity at a late stage
of disease. However, suppression of IFN-I production in an early
phase of infection might negatively affect immune recognition
and favor intracellular persistence and development of chronic
infections.
To date, it is further hard to foresee whether the induction
of IFN-I by TLR7/9-based vaccine adjuvants will be beneficial
by augmenting the preexisting memory response to S. aureus or
converting its effector function to increased protection. It is also
within the range of possibilities that these TLR agonists support
the tolerogenic response exerted toward a commensal pathogen
well-known to the host immune system.
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